Herceptin proven to benefit women with HER2 positive early breast cancer – latest results from the HERA study
Published on 10 March 2009 by Insciences
Study confirms Herceptin’s promise of extra years of living cancer free
The Breast International Group (BIG) in collaboration with Roche announced today that women with HER2 positive early breast cancer continue to benefit from Herceptin (trastuzumab) several years after treatment completion and as a result enjoy...
British team pioneers reconstruction technique using enriched tissue
Angela Brooks
The Observer, Sunday 8 March 2009
A remarkable reconstruction technique is being trialled by British surgeons, who are harvesting stem-cell-enriched fat from women's bodies to plug the dip often left by breast cancer operations.
The procedure appears to restore the softness and suppleness of breast tissues, undoing the damage frequently caused by lumpectomy and...
Last Updated: 2009-03-05 15:23:10 -0400 (Reuters Health)
By Scott Baltic
NEW YORK (Reuters Health) - Gene expression profiles based on analysis of tumor DNA microarrays can differentiate between breast cancers that are responsive to letrozole, an oral, non-steroidal, highly selective aromatase inhibitor, and those that are resistant to the drug. These results are from a study by an international group of researchers published online February 17 by the Journal of Clinical...
High Blood Pressure Linked To Earlier Death Among African-American Breast Cancer Patients
ScienceDaily (Mar. 4, 2009) — A study by researchers at the University of California, San Francisco has shown that hypertension, or high blood pressure, is a predictor of mortality among breast cancer patients, especially those who are African-American, and that hypertension accounts for approximately 30 percent of the survival disparity between African-American and white breast cancer patients....
LONDON, March 5 (Reuters) -
GlaxoSmithKline's breast cancer drug Tyverb has been turned down again in a final assessment by Britain's cost-effectiveness watchdog.
The National Institute for Health Clinical Excellence, which assesses drugs for reimbursement on the state health service, said on Thursday the treatment had limited benefits and was too expensive, even after a special deal offered by Glaxo.
